“Breakthrough T1D congratulates Dr. Kevan Herold on his appointment as the new TrialNet Chair. Dr. Herold has been a trusted Breakthrough T1D collaborator and partner since 1988 when he first received Breakthrough T1D funding. Over the past 33 years, Dr. Herold has worked tirelessly to advance our understanding of T1D, working alongside Breakthrough T1D to develop disease-modifying therapies that change the disease’s course. TrialNet is a clinical trial network critical to Breakthrough T1D’s research strategy, which tests potential therapies to prevent T1D.
Dr. Herold’s innovation is the immune-modulating drug, teplizumab, including four clinical trials in new-onset T1D and the landmark Teplizumab TrialNet Clinical Study. This study was conducted by TrialNet at the direction of Dr. Herold and Carla Greenbaum, M.D., and the first to demonstrate a delay in the onset of T1D in at-risk children and adults. This trial was an enormous step forward in the development of therapies to treat T1D. Without his work, this drug would not currently be under review at FDA. This study was funded in part by Breakthrough T1D and the National Institutes of Health via the Special Diabetes Program.
Breakthrough T1D would also like to thank Carla Greenbaum, M.D., for her years of service to the T1D community as the recent TrialNet Chair. Under her leadership, TrialNet conducted key research, including the groundbreaking Teplizumab Prevention Study. We look forward to continuing to work with her in her roles as Director of the TrialNet Hub and Clinical Center Director for the Benaroya Research Institute.”
– Breakthrough T1D Vice President of Research, Sanjoy Dutta, Ph.D.
